July 6, 2026

Dear all,

Company Name :	NITTOSEIKO CO., LTD.
Name of Representative :	Makoto Araga, Representative of Director and President (Securities code: 5957; Tokyo Stock Exchange Prime Market)
Contact information :	Shinichi Matsumoto, Director and General Manager of Corporate Administration Division (Telephone: +81-773-42-3111)

Notice Regarding the Grant of a Patent in the Kingdom of Thailand for a High-Purity Biodegradable Magnesium Material for Medical Use

We are pleased to announce that, following the granting of a Japanese patent in June 2023 and a U.S. patent in July 2024, we have now obtained a patent in the Kingdom of Thailand for the world's first "high-purity biodegradable magnesium material for medical use," for which we filed a patent application on February 18, 2021.

1. Country of Patent Registration: Kingdom of Thailand
2. Title of Invention: BIODEGRADABLE MEDICAL IMPLEMENT
3. Patent Number: No. 122078
4. Patent Registration: June 22, 2026
5. Patent Holder: NITTOSEIKO CO., LTD. and 4 others

This patent relates to a pure magnesium material for which the rate of dissolution and absorption within the body can be controlled (*1); in addition, international patent applications based on this patent are currently under examination in various countries.

Unlike conventional magnesium alloys, which contain high levels of impurities, the material covered by this patent is pure magnesium with a purity of 99.95% or higher. As a result, it exhibits extremely high biocompatibility, and we are actively pursuing its application and development in implant products that offer superior biocompatibility and safety.

*1 Control of the Dissolution and Absorption Period Within the Body
In the treatment of fractures, the dissolution rate of this material has been optimized so that it does not dissolve during the period required for bone union, but gradually dissolves and is absorbed after the bone has healed.

We believe this patent will enable the exclusive use of our technology in the ASEAN market and contribute to our future business expansion.

While the impact of this matter on our Group's financial results for the fiscal year ending December 2026 will be minimal, we believe it will contribute to improving our performance over the medium to long term.

End of document